Search

Your search keyword '"Fustier, P."' showing total 10 results
Start Over Author "Fustier, P." Journal hematological oncology
10 results on '"Fustier, P."'

1. MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA.

Author

Sehn, L., Sarkozy, C., Song, Y., Salar, A., Trotman, J., Zinzani, P. L., Zhang, J., Zhang, W., Fustier, P., Delarue, R., and Nastoupil, L.

Subjects
MUCOSA-associated lymphoid tissue lymphoma, RITUXIMAB, CLINICAL trials, LENALIDOMIDE, MAHOGANY, BRUTON tyrosine kinase
Abstract

Zanubrutinib is approved in >15 countries, including the United States and European Union, for pts with relapsed/refractory ( I R i / I R i ) marginal zone lymphoma (MZL) who received >=1 anti-CD20-based regimen, based on the single-arm MAGNOLIA trial (Opat et al. I Clin Cancer Res i 2021). B Introduction: b Inhibition of Bruton tyrosine kinase (BTK) has emerged as a strategy for treatment of patients (pts) with B-cell malignancies including indolent non-Hodgkin lymphomas. MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA. [Extracted from the article]

Published
2023
Full Text
View/download PDF

2. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2 ) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

Author

Leonard, J., primary, Trneny, M., additional, Izutsu, K., additional, Fowler, N., additional, Hong, X., additional, Zhang, H., additional, Offner, F., additional, Scheliga, A., additional, Nowakowski, G., additional, Pinto, A., additional, Re, F., additional, Fogliatto, L., additional, Scheinberg, P., additional, Flinn, I., additional, Moreira, C., additional, Czuczman, M., additional, Kalambakas, S., additional, Fustier, P., additional, Wu, C., additional, and Gribben, J., additional

Published
2019
Full Text
View/download PDF

3. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2 ) VS RITUXIMAB/PLACEBO (AUGMENT)

Author

Thieblemont, C., primary, Leonard, J., additional, Trneny, M., additional, Izutsu, K., additional, Fowler, N., additional, Hong, X., additional, Zhang, H., additional, Offner, F., additional, Scheliga, A., additional, Nowakowski, G., additional, Pinto, A., additional, Re, F., additional, Fogliatto, L., additional, Scheinberg, P., additional, Flinn, I., additional, Moreira, C., additional, Czuczman, M., additional, Kalambakas, S., additional, Fustier, P., additional, Wu, C., additional, and Gribben, J., additional

Published
2019
Full Text
View/download PDF

4. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2 ) THAN RITUXIMAB/PLACEBO

Author

Gribben, J., primary, Trneny, M., additional, Izutsu, K., additional, Fowler, N.H., additional, Hong, X., additional, Zhang, H., additional, Offner, F., additional, Scheliga, A., additional, Nowakowski, G., additional, Pinto, A., additional, Re, F., additional, Fogliatto, L., additional, Scheinberg, P., additional, Flinn, I., additional, Moreira, C., additional, Czuczman, M., additional, Kalambakas, S., additional, Fustier, P., additional, Wu, C., additional, and Leonard, J., additional

Published
2019
Full Text
View/download PDF

5. HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

Author

Leonard, J.P., primary, Trněny, M., additional, Izutsu, K., additional, Fowler, N.H., additional, Hong, X., additional, Zhang, H., additional, Offner, F., additional, Scheliga, A., additional, Nowakowski, G., additional, Pinto, A., additional, Re, F., additional, Fogliatto, L.M., additional, Scheinberg, P., additional, Flinn, I.W., additional, Moreira, C., additional, Tabah, A., additional, Abouzaid, S., additional, Kalambakas, S., additional, Fustier, P., additional, Wu, C., additional, and Gribben, J.G., additional

Published
2019
Full Text
View/download PDF

7. HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO.

Author

Leonard, J.P., Trněny, M., Izutsu, K., Fowler, N.H., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L.M., Scheinberg, P., Flinn, I.W., Moreira, C., Tabah, A., Abouzaid, S., Kalambakas, S., Fustier, P., and Wu, C.

Subjects
QUALITY of life, RITUXIMAB
Published
2019
Full Text
View/download PDF

8. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO.

Author

Gribben, J., Trneny, M., Izutsu, K., Fowler, N.H., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S., Fustier, P., Wu, C., and Leonard, J.

Subjects
THERAPEUTICS, RITUXIMAB, PLACEBOS, STOCK ownership
Published
2019
Full Text
View/download PDF

9. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS.

Author

Leonard, J., Trneny, M., Izutsu, K., Fowler, N., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S., Fustier, P., Wu, C., and Gribben, J.

Subjects
RITUXIMAB, PLACEBOS
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results